FOURKITES
15.12.2022 09:01:40 CET | Business Wire | Press release
Leading supply chain visibility company FourKites today announces strong global growth during 2022, as the company executed on its vision for automated, interconnected and collaborative supply chains that span transportation, warehouses, stores, trucks and more. The company realised 70% growth in new customers, with more than 1,200 of the world’s most recognised brands now using FourKites to track more than 3M shipments around the world every day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221215005097/en/
FourKites Extends its Leadership Position in the Supply Chain Visibility Market with a Year of Strong Growth & Innovation (Photo: Business Wire)
Among the new customers who are using FourKites to transform their supply chains are QVC, Ahold Delhaize, Volvo Group, Rohlig Logistics, Fiberpartner, Chevron Corporation, SpaceX, Molson Coors, Bacardi and 3T — further validating Gartner’s ranking of FourKites as a Leader in the 2022 Gartner® Magic Quadrant™ for Real-time Transportation Visibility Solutions, and the visibility provider of choice for customers with the most complex supply chain needs.1
In 2022, FourKites achieved the following in Europe:
- 2X growth in European shipments, across 120 countries and territories
- 40% growth in European customers
- 24% growth in the number of carriers tracking shipments
- 2.4B+ miles tracked in the region
Industry giants back FourKites’ long-term vision of supply chain transformation
In addition to strategic investments in 2021 from industry heavyweights Qualcomm Ventures, LLC, Volvo Group Venture Capital AB and Zebra Technologies, over the past year, FourKites inked strategic partnerships with a number of industry titans to continue executing on its bold vision for the future of digital supply chains. These companies include FedEx, Quiet Platforms, Mitsui & Co., Ltd., Sony, Microsoft and Narvar. The real-time supply chain visibility pioneer was also recognised for its industry leadership and ongoing innovation by Gartner, SupplyChainBrain, Blue Yonder, Builtin Chicago, Manhattan Associates and Food Shippers of America.
Unique customer collaboration model continues to deliver industry-first innovations
Close collaboration with customers has been the bedrock of FourKites’ product development since the company’s inception. More than nine out of 10 FourKites customers are active contributors to the company’s IdeaExchange, and FourKites’ Innovation Partner program has generated more than 200 product enhancements from more than 70 companies, including Andersen Corporation, Canfor, Cardinal Health, Ecolab, Henkel, Kimberly-Clark, Smithfield and Sprouts Farmers Market, among others.
New solutions released in 2022 include:
-
New detention & demurrage capabilities to help shippers more quickly and proactively identify potential detention and demurrage fees; prioritise exceptions according to likely business impact; and proactively adjust carriers, lanes or other factors as necessary.
- “FourKites’ automated reporting and tracking for ocean provides more accurate and real-time data, which allows Canfor to respond to customer inquiries quicker with up-to-date information on our upcoming shipments that would have otherwise had to be manually tracked.” — Bob Hayes, Vice President of Global Supply Chain at Canfor
- Patented ocean shipment innovations that provide international shippers and their partners with complete visibility into all of the complex documentation requirements at every leg of every ocean shipment.
-
A Net Zero initiative to help companies reduce supply chain emissions, including FourKites’ Sustainability Hub, a suite of analytics tools to provide better visibility into resource consumption and waste generation; a new Sustainability Advisory Board; and ongoing original research around sustainability.
- “To track emissions and to evaluate how we’re performing — it all relies on data. And that’s a place where we’ve been thrilled with our partnership with FourKites, because without it, we would not have the critical data we need to operate well.” — Karen Betancourt, Vice President of Logistics at Cardinal Health
-
A new unified customer interface that integrates real-time transportation visibility and facility-specific data across all modes.
- “FouKites continues to excel and impress me with their ability to deliver tools that are useful and support our account in a way that is customer first. In working with them, they have been able to roll out coverage in multiple countries, manage the work, and enhance their tool along the way. I’m very impressed with their product and the agility in delivery.” — Logistics Strategy Analyst, Manufacturing
"In the past year, we worked closely with our community of supply chain leaders and partners to introduce valuable solutions and insights to better manage inventory, drive efficiencies in supplier ecosystems, streamline international shipments, improve sustainability — and so much more," says FourKites founder and CEO Mathew Elenjickal. "In 2023, we look forward to helping our customers take the next leap forward in their logistics operations, expanding their insight further into their network and at the SKU level. Together, we will build a more resilient and agile supply chain."
About FourKites
Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
1 Gartner, Critical Capabilities for Real-Time Transportation Visibility Platforms, Carly West, 24 May 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005097/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
